![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis:
An Analysis of ALLY-3 and ALLY-3+
|
|
|
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Kowdley KV,1 Angus P,2 Bernstein D,3 Bronowicki J-P,4 Leroy V,5 Pockros PJ,6 Bhore R,7 Rana K,8 Jimenez-Exposito MJ7
1Swedish Medical Center, Seattle, WA; 2Austin Hospital, Heidelberg, Australia; 3Hofstra North Shore-Long Island Jewish School of Medicine, Seattle, WA; 4CHU Nancy & Lorraine University, Nancy, France; 5CHU de Grenoble,
La Tronche, France; 6Scripps Clinic, La Jolla, CA; 7Bristol-Myers Squibb Research & Development, Princeton, NJ; 8Bristol-Myers Squibb Research & Development, Wallingford, CT
![EASL1](../images/042016/042016-9/EASL1.gif)
![EASL2](../images/042016/042016-9/EASL2.gif)
![EASL3](../images/042016/042016-9/EASL3.gif)
![EASL4](../images/042016/042016-9/EASL4.gif)
![EASL5](../images/042016/042016-9/EASL5.gif)
![EASL6](../images/042016/042016-9/EASL6.gif)
![EASL7](../images/042016/042016-9/EASL7.gif)
![EASL8](../images/042016/042016-9/EASL8.gif)
![EASL9](../images/042016/042016-9/EASL9.gif)
![EASL10](../images/042016/042016-9/EASL10.gif)
![EASL11](../images/042016/042016-9/EASL11.gif)
![EASL12](../images/042016/042016-9/EASL12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|